Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Vardiman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia Research|September 4, 2012
The classification of MDS: from FAB to WHO and beyondJames Vardiman
American Journal of Clinical Pathology|June 14, 2015
Acute Myeloid Leukemia With Myelodysplasia-Related ChangesJames Vardiman, Kaaren Reichard
Hematology. American Society of Hematology. Education Program|December 14, 2011
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variantsJames Vardiman, Elizabeth Hyjek
American Journal of Clinical Pathology|April 19, 2013
A subset of Rosai-Dorfman disease exhibits features of IgG4-related diseaseXuefeng Zhang, Elizabeth Hyjek, James Vardiman
Hematology. American Society of Hematology. Education Program|November 25, 2004
Myelodysplastic syndromesAlan F List, James Vardiman, Jean-Pierre J Issa, et al.
The American Journal of Dermatopathology|April 12, 2019
The Conundrum of Diagnosing Cutaneous Composite Lymphoma in the Molecular AgeAadil Ahmed, Alessa P Aragao, Kumaran Mudaliar, et al.
Nature Communications|April 11, 2018
Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemiaZejuan Li, Hao Huang, Ping Chen, et al.
Nature Communications|February 23, 2012
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemiaZejuan Li, Hao Huang, Ping Chen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia Research|September 4, 2012
The classification of MDS: from FAB to WHO and beyondJames Vardiman
American Journal of Clinical Pathology|June 14, 2015
Acute Myeloid Leukemia With Myelodysplasia-Related ChangesJames Vardiman, Kaaren Reichard
Hematology. American Society of Hematology. Education Program|December 14, 2011
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variantsJames Vardiman, Elizabeth Hyjek
American Journal of Clinical Pathology|April 19, 2013
A subset of Rosai-Dorfman disease exhibits features of IgG4-related diseaseXuefeng Zhang, Elizabeth Hyjek, James Vardiman
Hematology. American Society of Hematology. Education Program|November 25, 2004
Myelodysplastic syndromesAlan F List, James Vardiman, Jean-Pierre J Issa, et al.
The American Journal of Dermatopathology|April 12, 2019
The Conundrum of Diagnosing Cutaneous Composite Lymphoma in the Molecular AgeAadil Ahmed, Alessa P Aragao, Kumaran Mudaliar, et al.
Nature Communications|April 11, 2018
Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemiaZejuan Li, Hao Huang, Ping Chen, et al.
Nature Communications|February 23, 2012
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemiaZejuan Li, Hao Huang, Ping Chen, et al.
Pageof 1